A XM não fornece serviços a residentes nos Estados Unidos da América.

A XM não fornece serviços a residentes nos Estados Unidos da América.
B
B

Biogen

Notícias

Reuters - Há 4 horas

Novo owner backs Swiss biotech Asceneuron in $100 million round

Novo owner backs Swiss biotech Asceneuron in $100 million round By Maggie Fick LONDON, July 16 (Reuters) - Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer's disease drug. The Series C round was led by Novo Holdings, the investment arm of the Novo Nordisk Foundation, which will hold a board seat on the Lausanne-based company.
B
Reuters - Há 15 horas

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Charter Communications Inc CHTR.OQ +4.1% Baker Hughes Co BKR.OQ +4% Fastenal Co FAST.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% Paychex Inc PAYX.OQ +2.7% Bottom Performers Percent Change Dollar Tree Inc DLTR.OQ -3.4% Biogen Inc BIIB.OQ -3.4% PDD Holdings Inc PDD.OQ -2.8% Lululemon Athletica Inc LULU.OQ -2.7% Starbucks Corp SBUX.OQ -2.5% The Nasdaq 100 .NDX gained 39.49 points,
B
C
F
L
P
S
D
U
D
P
Reuters - Há 19 horas

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +4.8% Baker Hughes Co BKR.OQ +4.4% Charter Communications Inc CHTR.OQ +3.7% Old Dominion Freight Line Inc ODFL.OQ +3.4% Fastenal Co FAST.OQ +3.3% Bottom Performers Percent Change PDD Holdings Inc PDD.OQ -2.4% Dollar Tree Inc DLTR.OQ -2.3% Xcel Energy Inc XEL.OQ -2.1% Ross Stores Inc ROST.OQ -1.9% Biogen Inc BIIB.OQ -1.9% The Nasdaq 100 .NDX gained 163.39 points,
B
C
F
T
X
D
R
U
P
O
Reuters - Há 4 dias

U.S. STOCKS Deckers Outdoor, Amgen, BlackRock

BUZZ-U.S. STOCKS ON THE MOVE-Deckers Outdoor, Amgen, BlackRock Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow touched a record high on Friday as this year's lagging stocks gained favor on optimism that the U.S. Federal Reserve will begin easing monetary policy in September, while big lenders fell after reporting mixed results.
A
A
B
C
I
J
T
R
U
U
E
T
Reuters - Há 4 dias

Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi

BUZZ-Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi Updates ** Shares of B iogen BIIB.O down more than 4% to ~$227 in afternoon trading * * Brokerage Piper Sandler cuts B iogen's stock PT to $313 from $335, slashing its near- and long-term sales outlook for co's Alzheimer's disease (AD) drug, Leqembi ** Says its new April-June survey data indicates Leqembi continues to face meaningful uptake barriers and doctors indicate relatively tepid uptake dynamics ** Mor
B
Reuters - Há 4 dias

U.S. STOCKS Estee Lauder, Deckers Outdoor, Amgen

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Deckers Outdoor, Amgen Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Friday as slightly hotter-than-expected producer price numbers did little to change bets around a U.S.
A
A
B
C
J
T
R
U
U
E
T
Reuters - Há 4 dias

U.S. STOCKS U.S. banks, Tesla, Snowflake

BUZZ-U.S. STOCKS ON THE MOVE-U.S. banks, Tesla, Snowflake Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set for a subdued open on Friday as investors digested mixed results from big banks, while slightly hotter-than-expected producer price numbers reined in bets that the Federal Reserve would begin easing interest rates in September.
A
B
C
J
T
R
U
T
Reuters - Há 4 dias

U.S. STOCKS Tesla, Teck Resources, JPMorgan

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Teck Resources, JPMorgan Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. index futures struggled for direction on Friday as investors parsed a set of big bank earnings to gauge the health of corporate America, while awaiting key inflation data for clues on the timing of interest rate cuts.
B
B
J
T
R
U
T
Reuters - Há 4 dias

Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi

BUZZ-Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi ** Brokerage Piper Sandler cuts Biogen's BIIB.O stock PT to $313 from $335, slashing its near- and long-term sales outlook for co's Alzheimer's disease (AD) drug, Leqembi ** Says its new April-June survey data indicates Leqembi continues to face meaningful uptake barriers and doctors indicate relatively tepid uptake dynamics ** More than halves FY'25 sales est.
B
Reuters - Há 2 semanas

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - Há 2 semanas

Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen

BUZZ-Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen ** The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's under the brand name Kisunla, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients *
B
Reuters - Há 2 semanas

Eli Lilly Alzheimer's drug approved by US FDA

UPDATE 3-Eli Lilly Alzheimer's drug approved by US FDA Adds Leqembi comparison, expert and analyst comments in paragraphs 5-16 By Julie Steenhuysen and Mariam Sunny July 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S.
B
Reuters - Há 2 semanas

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japan's Eisai developing dementia drug for US market, Nikkei reports TOKYO, June 30 (Reuters) - Japanese drugmaker Eisai 4523.T is developing a d ementia treatment that it aims to commerciali s e in the U.S. by fiscal 2030, the Nikke i r eported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
B
Reuters - Há 3 semanas

Eisai and Biogen launch Alzheimer's drug Leqembi in China

Eisai and Biogen launch Alzheimer's drug Leqembi in China June 28 (Reuters) - Eisai 4523.T and Biogen BIOAb.ST have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
B
Reuters - Há 3 semanas

Biogen has up to $10 billion for its next M&A bets- Bloomberg News

MEDIA-Biogen has up to $10 billion for its next M&A bets- Bloomberg News -- Source link: https://tinyurl.com/3w57zmcr -- Note: Reuters has not verified this story and does not vouch for its accuracy
B
Reuters - Há 3 semanas

Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union

BRIEF-Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union June 24 (Reuters) - Biogen Inc BIIB.O : TOFIDENCE™ (TOCILIZUMAB), A BIOSIMILAR REFERENCING ROACTEMRA®, APPROVED IN THE EUROPEAN UNION Source text for Eikon: ID:nGNE95yLRY Further company coverage: BIIB.O
B
Reuters - Há 4 semanas

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +6.8% Tesla Inc TSLA.OQ +5.8% Broadcom Inc AVGO.OQ +5.7% Micron Technology Inc MU.OQ +4.7% Synopsys Inc SNPS.OQ +4.0% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -3.2% Atlassian Corp TEAM.OQ -2.4% Biogen Inc BIIB.OQ -2.2% ON Semiconductor Corp ON.OQ -2.0% Marvell Technology Inc MRVL.OQ -1.8% The Nasdaq 100 .NDX gained 287.51 points, or
A
B
B
M
M
T
W
O
U
A
S
Reuters - Há 1 mês

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds By Christy Santhosh June 13(Reuters) - Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on Thursday. The report issued by the U.S.
B
Reuters - Há 1 mês

Biogen executive plays down looming competition for its Alzheimer's drug

UPDATE 1-Biogen executive plays down looming competition for its Alzheimer's drug Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11 By Sriparna Roy June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
B
G
Reuters - Há 1 mês

Biogen executive says its Alzheimer's drug will do well in market despite competition

Biogen executive says its Alzheimer's drug will do well in market despite competition June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editi
B

Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.